Press release
Amyloidosis Market to Accelerate Substantially by 2032, estimates DelveInsight
Key Takeaways from the Amyloidosis Market Research Report
* The increase in Amyloidosis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
* As per DelveInsight analysis, the Amyloidosis Market is anticipated to witness growth at a considerable CAGR.
* The leading Amyloidosis Companies working in the market include Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutiscs, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, United BioSource LLC, and others
* Promising Amyloidosis Therapies in the various stages of development include AT-02, Carfilzomib, Dexamethasone, VELCADE, NTLA-2001, GSK2398852, Eplontersen, and others.
* April 2024:- Attralus Inc.- A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02. This is a multicenter, international, three-part, Phase 1 study designed to evaluate the safety, tolerability, and PK of rising single doses of AT-02 in healthy volunteers and in subjects with systemic amyloidosis and to assess the safety, tolerability, and PK of multiple doses of AT-02 in subjects with systemic amyloidosis.
* April 2024:- Intellia Therapeutics- MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM). To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
* April 2024:- Akcea Therapeutics- A Prospective, Non-interventional, Long-term, Multinational Cohort Safety Study of Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (hATTR-PN). This is a prospective, non-interventional, Long-term, multinational cohort safety study of patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (hATTR-PN). The overarching goal of this study is to further characterize the long-term safety of TEGSEDI (inotersen) in patients with hATTR-PN under real-world conditions.
Discover which therapies are expected to grab the Amyloidosis Market Share @ Amyloidosis Market Outlook [https://www.delveinsight.com/sample-request/amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Amyloidosis Overview
Amyloidosis is a group of diseases characterized by the abnormal buildup of a protein called amyloid in various organs and tissues of the body. Amyloid is a protein that normally circulates in the blood, but in amyloidosis, it becomes misfolded and clumps together to form insoluble fibers. These fibers can accumulate in different organs such as the heart, kidneys, liver, spleen, nervous system, and digestive tract, interfering with their normal function and leading to organ damage and failure.
Amyloidosis Epidemiology Insights
The epidemiology section of Amyloidosis offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.
Download the report to understand which factors are driving Amyloidosis Epidemiology trends @ Amyloidosis Epidemiological Insights [https://www.delveinsight.com/sample-request/amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Amyloidosis Drugs Market
The Amyloidosis Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Amyloidosis signaling in Amyloidosis are likely to uncover new therapeutic targets and further expand treatment options for patients.
Amyloidosis Treatment Market Landscape
The Amyloidosis treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Amyloidosis has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
To learn more about Amyloidosis treatment guidelines, visit @ Amyloidosis Treatment Market Landscape [https://www.delveinsight.com/sample-request/amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Amyloidosis Market Outlook
The report's outlook on the Amyloidosis market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Amyloidosis therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Amyloidosis drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Amyloidosis market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.
Amyloidosis Drugs Uptake
The drug chapter of the Amyloidosis report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Amyloidosis.
Major Amyloidosis Companies
Several Amyloidosis Companies working in the market include Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutics, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, United BioSource LLC, and others
Learn more about the FDA-approved drugs for Amyloidosis @ Drugs for Amyloidosis Treatment [https://www.delveinsight.com/sample-request/amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Amyloidosis Market Report
* Coverage- 7MM
* Amyloidosis Companies- Attralus Inc., Novotech Pty Limited, Criterium Inc., Amgen, Millennium Pharmaceuticals Inc., Johnson & Johnson Pharmaceuticals, Intellia Therapeutiscs, Regeneron Pharmaceuticals, Akcea Therapeutics, GlaxoSmithKline, United BioSource LLC, and others
* Amyloidosis Therapies- AT-02, Carfilzomib, Dexamethasone, VELCADE, NTLA-2001, GSK2398852, Eplontersen, and others.
* Amyloidosis Market Dynamics: Amyloidosis Market Drivers and Barriers
* Amyloidosis Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Amyloidosis Drugs in development @ Amyloidosis Clinical Trials Assessment [https://www.delveinsight.com/sample-request/amyloidosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis
4. Amyloidosis: Market Overview at a Glance
5. Amyloidosis: Disease Background and Overview
6. Patient Journey
7. Amyloidosis Epidemiology and Patient Population
8. Amyloidosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Amyloidosis Unmet Needs
10. Key Endpoints of Amyloidosis Treatment
11. Amyloidosis Marketed Products
12. Amyloidosis Emerging Therapies
13. Amyloidosis: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Amyloidosis
17. KOL Views
18. Amyloidosis Market Drivers
19. Amyloidosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=amyloidosis-market-to-accelerate-substantially-by-2032-estimates-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Amyloidosis Market to Accelerate Substantially by 2032, estimates DelveInsight here
News-ID: 3475567 • Views: …
More Releases from ABNewswire
Schneider Electric says Chinese market remains important
Schneider Electric has established R & D centers in multiple Chinese cities including Beijing, Shanghai, Wuxi, Xi'an and Shenzhen.
HANNOVER, Germany - May 4, 2024 - A senior executive of Schneider Electric said that the Chinese market remains important, a fact that "has not changed."
Barbara Frei, the company's executive vice president, made the remarks during an interview with Xinhua at the ongoing Hannover Messe 2024 Trade Fair.
"The importance of the Chinese…
Schneider Electric Boosts Industrial Competitiveness
Schneider Electric is said to showcase the latest innovations in its portfolio, including industrial software, Artificial Intelligence and Digital Twin technology. These solutions will be demonstrated through the lens of a digital and sustainable life science campus, highlighting Schneider's deep domain expertise across the entire industrial value chain.
"With industry contributing around 45% of global greenhouse gas emissions, it is clear we must act to reduce this and support industrial decarbonization…
Essential Guide to Residential Electrical Repair
From addressing minor issues like flickering lights to more complex tasks such as rewiring circuits, residential electrical repair encompasses a wide range of services aimed at maintaining the integrity of the electrical infrastructure.
Residential electrical repair is a critical aspect of homeownership, ensuring the safety, functionality, and efficiency of electrical systems within the home. From addressing minor issues like flickering lights to more complex tasks such as rewiring circuits, residential electrical…
Mastering Electrical Repairs: Contractor Chronicles
In the realm of electrical repairs, the expertise and finesse of an electrical repair contractor [https://maps.app.goo.gl/YWBMnbQFW5rD5S7L9#electrical-repair-contractor] or company can make all the difference. These professionals are the backbone of ensuring the safety, functionality, and efficiency of electrical systems in residential, commercial, and industrial settings. Their role goes beyond mere troubleshooting; it encompasses a comprehensive understanding of electrical systems, adherence to safety protocols, and the ability to deliver timely and effective…
More Releases for Amyloid
Amyloid Peptides Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Amyloid Peptides Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Amyloid Peptides players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyloid Peptides with respect to individual growth…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
Familial Amyloid Cardiomyopathy Treatment Market Opportunity Analysis, 2018–20 …
Aggregation and deposition of mutant and wild-type transthyretin protein (TTR) in heart results in familial amyloid cardiomyopathy, which typically occur after age of 60. Familial amyloid cardiomyopathy is also known as hereditary cardiac transthyretin amyloidosis or hereditary amyloid cardiomyopathy. The protein transthyretin amyloid fibrils infiltrate the myocardium that leads to diastolic dysfunction from restrictive cardiomyopathy, which eventually result to heart failure. There are several mutation in TTR which are associated…
Familial Amyloid Neuropathies Pharmaceutical and Healthcare Analysis Information
Summary
Familial amyloid neuropathy is a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues. Symptoms include numbness, tingling, pins and needles in the feet and hands, weakness and pain in the arms and legs, loss of sensation, urinary retention, reduced sweating, ankle swelling, fatigue, nausea, weight loss, dizziness and fainting. Supportive treatment includes diuretics, calcium channel blockers,…
Islet Amyloid Polypeptide Market Trends & Forecast to 2022
HTF MI published a new industry research that focuses on Islet Amyloid Polypeptide market and delivers in-depth market analysis and future prospects of Global Islet Amyloid Polypeptide market. The study covers significant data which makes the research document a handy resource for managers, analysts, industry experts and other key people get ready-to-access and self-analyzed study along with graphs and tables to help understand market trends, drivers and market challenges. The…
